Document Type : Short Communication

Authors

1 M.Sc. of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran

2 Professor, Radiation Biology Research Center, Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran

3 Assistant Professor, Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran

4 Assistant Professor, Subspecialty of Endocrinology and Metabolism, Endocrine Research Center, Firouzgar Hospital, Department of Endocrinology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Abstract

Introduction: Diabetic neuropathy is a common and sever complication of diabetes that its progression can lead to disability and even amputation in diabetic patients. The aim of this study was to determine the effective factors in the event of neuropathy and to assess the cumulative incidence of neuropathy in patients with type 2 diabetes.
Methods: In this cohort study, all patients with type 2 diabetes who were registered at Fereydunshahr Diabetes Clinic, Isfahan, Iran, were selected by census method. They were followed up for diagnosis of neuropathy since 2006 until March 2016. To investigate the quantitative and qualitative effective factors in the event of neuropathy, one-sample t-test and chi-square test, respectively, were used. And for modeling of effective factors in the event of neuropathy, logistic regression was used. All statistics were analyzed by R software (version 3.2.3) and P values less than 0.05 were considered significant.
Results: At the end of 10-year follow-up, cumulative incidence and prevalence of neuropathy were estimated 31% and 41.6%, respectively. After removal of confounders in the final model, variables such as age, ethnicity, family history of diabetes, duration of diabetes, FBS and HDL levels were identified as effective factors in the event of neuropathy (p <0.05).
Conclusion: Low levels of HDL and poor control of FBS level are modifiable risk factors for diabetic neuropathy. But non-modifiable risk factors include Persian ethnicity, family history of diabetes, age and increase of diabetes duration. For this reason, in order to increase the HDL level and to decrease FBS level, education is recommended particularly in elderly patients with a family history of diabetes.
 

Keywords

  1. Morgan CL, McEwan P, Morrissey M, Peters JR, Poole C, Currie CJ. Characterization and comparison of health-related utility in people with diabetes with various single and multiple vascular complications. Diabet Med 2006;23(10):1100-5.
  2. Mueller MJ. Identifying patients with diabetes mellitus who are at risk for lower-extremity complications: use of Semmes-Weinstein monofilaments. Phys Ther 1996;76(1):68-71.
  3. Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996;39(11):1377-84.
  4. Nitiyanant W, Tandhanand S, Mahtab H, Zhu XX, Pan CY, Raheja BS, et al. The Diabcare-Asia 1998 study--outcomes on control and complications in type 1 and type 2 diabetic patients. Curr Med Res Opin 2002;18(5):317-27.
  5. Janghorbani M, Rezvanian H, Kachooei A, Ghorbani A, Chitsaz A, Izadi F, et al. Peripheral neuropathy in type 2 diabetes mellitus in Isfahan, Iran: prevalence and risk factors. Acta Neurol Scand 2006;114(6):384-91.
  6. Zeiqler D. Current Evidence For Treating Diabetic Neuropathy. Journal of the Peripheral Nervous System 2000; 5(3): 172-5.
  7. Rahman M, Griffin SJ, Rathmann W, Wareham NJ. How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-based comparison of four measures. Diabet Med 2003;20(5):368-74.
  8. Tabatabaei-Malazy O, Mohajeri-Tehrani M, Madani S, Heshmat R, Larijani B. The prevalence of diabetic peripheral neuropathy and related factors. Iran J Public Health 2011;40(3):55-62.
  9. Sobhani S, Asayesh H, Sharifi F, Djalalinia S, Baradaran HR, Arzaghi SM, et al. Prevalence of diabetic peripheral neuropathy in Iran: a systematic review and meta-analysis. J Diabetes Metab Disord 2014;13(1):97.
  10. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005;352(4):341-50.
  11. Lloyd CE, Becker D, Ellis D, Orchard TJ. Incidence of complications in insulin-dependent diabetes mellitus: a survival analysis. Am J Epidemiol 1996;143(5):431-41.
  12. Orchard TJ, Forrest KY, Kuller LH, Becker DJ, Pittsburgh Epidemiology of Diabetes Complications Study. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care 2001;24(6):1053-9.
  13. Sands ML, Shetterly SM, Franklin GM, Hamman RF. Incidence of distal symmetric (sensory) neuropathy in NIDDM. The San Luis Valley Diabetes Study. Diabetes Care 1997;20(3):322-9.
  14. Maser RE, Steenkiste AR, Dorman JS, Nielsen VK, Bass EB, Manjoo Q, et al. Epidemiological correlates of diabetic neuropathy. Report from Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1989;38(11):1456-61.
  15. Boru UT, Alp R, Sargin H, Kocer A, Sargin M, Luleci A, et al. Prevalence of peripheral neuropathy in type 2 diabetic patients attending a diabetes center in Turkey. Endocr J 2004;51(6):563-7.
  16. Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG. A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. Diabetes Care 1999;22(7):1036-42.
  17. McNeely MJ, Boyko EJ, Ahroni JH, Stensel VL, Reiber GE, Smith DG, et al. The independent contributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks? Diabetes Care 1995;18(2):216-9.
  18. Trivedi JR, Phillips L, Chhabra A. Hereditary and acquired polyneuropathy conditions of the peripheral nerves: clinical considerations and MR neurography imaging. Semin Musculoskelet Radiol 2015;19(2):130-6.
  19. Tavakkoly-Bazzaz J, Amoli MM, Pravica V, Chandrasecaran R, Boulton AJ, Larijani B, et al. VEGF gene polymorphism association with diabetic neuropathy. Mol Biol Rep 2010;37(7):3625-30.
  20. Kargarian Marvasti S, Abolghasemi J, Heydari I, Rimaz S. Effective Factors in the Time of Development of Neuropathy in Type II Diabetic Patients. Iranian Journal of Epidemiology. 2017;13(2):80-9
  21. Kargarian-Marvasti S, Rimaz S, Abolghasemi J, Heydari I. Comparing of Cox model and parametric models in analysis of effective factors on event time of neuropathy in patients with type 2 diabetes. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. 2017;22:115.